ECSP21001786A - Degradadores selectivos del receptor de estrógeno - Google Patents

Degradadores selectivos del receptor de estrógeno

Info

Publication number
ECSP21001786A
ECSP21001786A ECSENADI20211786A ECDI202101786A ECSP21001786A EC SP21001786 A ECSP21001786 A EC SP21001786A EC SENADI20211786 A ECSENADI20211786 A EC SENADI20211786A EC DI202101786 A ECDI202101786 A EC DI202101786A EC SP21001786 A ECSP21001786 A EC SP21001786A
Authority
EC
Ecuador
Prior art keywords
selective
receptor degraders
strogen
strogen receptor
degraders
Prior art date
Application number
ECSENADI20211786A
Other languages
English (en)
Inventor
Daniel Jon Sall
Jeffrey Daniel Cohen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67480324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21001786(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21001786A publication Critical patent/ECSP21001786A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Ver resumen adjunto.
ECSENADI20211786A 2018-07-12 2021-01-11 Degradadores selectivos del receptor de estrógeno ECSP21001786A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
US201962825172P 2019-03-28 2019-03-28

Publications (1)

Publication Number Publication Date
ECSP21001786A true ECSP21001786A (es) 2021-02-26

Family

ID=67480324

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20211786A ECSP21001786A (es) 2018-07-12 2021-01-11 Degradadores selectivos del receptor de estrógeno

Country Status (33)

Country Link
US (1) US12128040B2 (es)
EP (1) EP3820874B1 (es)
JP (1) JP7085056B2 (es)
KR (1) KR102577142B1 (es)
CN (1) CN112424205B (es)
AU (1) AU2019299952B2 (es)
BR (1) BR112020025381A2 (es)
CA (1) CA3105491C (es)
CL (1) CL2021000046A1 (es)
CO (1) CO2021000041A2 (es)
CR (1) CR20210006A (es)
DK (1) DK3820874T3 (es)
EC (1) ECSP21001786A (es)
ES (1) ES2932867T3 (es)
FI (1) FI3820874T3 (es)
HR (1) HRP20230080T1 (es)
HU (1) HUE061032T2 (es)
IL (1) IL279990B2 (es)
JO (1) JOP20210004B1 (es)
LT (1) LT3820874T (es)
MD (1) MD3820874T2 (es)
MX (1) MX2021000377A (es)
MY (1) MY210254A (es)
PE (1) PE20211245A1 (es)
PH (1) PH12021550048A1 (es)
PL (1) PL3820874T3 (es)
PT (1) PT3820874T (es)
RS (1) RS63876B1 (es)
SA (1) SA521421006B1 (es)
SG (1) SG11202100145YA (es)
SI (1) SI3820874T1 (es)
UA (1) UA125890C2 (es)
WO (1) WO2020014440A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102710603B1 (ko) 2015-10-01 2024-09-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
WO2017104739A1 (ja) 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
US11395820B2 (en) 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
SG11202012464WA (en) 2018-07-11 2021-01-28 H Lee Moffitt Cancer Center And Research Institute Inc Dimeric immuno-modulatory compounds against cereblon-based mechanisms
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
JP7616794B2 (ja) 2019-07-07 2025-01-17 オレマ ファーマシューティカルズ インク. エストロゲン受容体アンタゴニストのレジメン
TWI894443B (zh) * 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
EP4361143A4 (en) * 2021-08-31 2025-05-28 Eisai R&D Management Co., Ltd. Process for the preparation of a monocyclic pyridine derivative
US11926634B2 (en) * 2022-02-01 2024-03-12 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
JP2025528249A (ja) 2022-08-25 2025-08-26 サノフイ 新規な置換キノリン及びテトラヒドロナフタレンカルボン酸誘導体並びにその治療的使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
CA2218756A1 (en) * 1996-10-25 1998-04-25 Kristin Sue Marron Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators
US7056931B2 (en) * 2001-05-22 2006-06-06 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
EP1497277A1 (en) * 2002-04-19 2005-01-19 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
DE20301728U1 (de) * 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
ATE476428T1 (de) * 2004-01-22 2010-08-15 Lilly Co Eli Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen
CA2578164A1 (en) * 2004-09-07 2006-03-16 Wyeth 6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
WO2014205136A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
US9845291B2 (en) * 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
CN107531722B (zh) * 2015-05-26 2020-07-17 豪夫迈·罗氏有限公司 杂环雌激素受体调节剂及其用途
JP7241542B2 (ja) * 2016-04-08 2023-03-17 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用
TWI823845B (zh) * 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
WO2020014440A1 (en) 2020-01-16
US12128040B2 (en) 2024-10-29
CL2021000046A1 (es) 2021-06-25
RS63876B1 (sr) 2023-02-28
JOP20210004A1 (ar) 2021-01-10
PH12021550048A1 (en) 2021-09-20
NZ771719A (en) 2024-02-23
UA125890C2 (uk) 2022-06-29
IL279990B2 (en) 2023-07-01
US20210260052A1 (en) 2021-08-26
MX2021000377A (es) 2021-03-25
HUE061032T2 (hu) 2023-05-28
CA3105491C (en) 2023-09-05
SG11202100145YA (en) 2021-02-25
IL279990A (en) 2021-03-01
KR102577142B1 (ko) 2023-09-12
PL3820874T3 (pl) 2023-02-06
SA521421006B1 (ar) 2023-02-08
CR20210006A (es) 2021-02-05
FI3820874T3 (fi) 2023-03-06
AU2019299952B2 (en) 2022-06-16
EP3820874A1 (en) 2021-05-19
EP3820874B1 (en) 2022-11-30
ES2932867T3 (es) 2023-01-27
KR20210018460A (ko) 2021-02-17
PT3820874T (pt) 2023-01-06
CO2021000041A2 (es) 2021-01-18
MY210254A (en) 2025-09-04
PE20211245A1 (es) 2021-07-13
MD3820874T2 (ro) 2023-05-31
HRP20230080T1 (hr) 2023-03-17
JOP20210004B1 (ar) 2024-04-18
LT3820874T (lt) 2023-02-10
AU2019299952A1 (en) 2021-01-21
JP2021530486A (ja) 2021-11-11
DK3820874T3 (da) 2022-12-12
CA3105491A1 (en) 2020-01-16
CN112424205B (zh) 2023-10-31
CN112424205A (zh) 2021-02-26
BR112020025381A2 (pt) 2021-03-09
SI3820874T1 (sl) 2023-02-28
JP7085056B2 (ja) 2022-06-15
IL279990B1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
ECSP21001770A (es) Degradadores selectivos del receptor de estrógeno
ECSP21001786A (es) Degradadores selectivos del receptor de estrógeno
CL2019001554S1 (es) Automóvil.
CL2018000947S1 (es) Automóvil
PT3494133T (pt) Recetores de células t anti-kras-g12d
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
CL2020000174S1 (es) Automóvil.
ECSP17015977A (es) Terapia de combinacion
CL2020001572A1 (es) Dispositivo de tuberias ranuradas.
EP3627868C0 (en) DEVICE PAIRING SYSTEM
CL2019002232S1 (es) Automóvil.
CL2018001940S1 (es) Automóvil
EP3801134A4 (en) SEAT ARRANGEMENT
CL2020001201S1 (es) Automóvil.
CL2018003838S1 (es) Botella.
EP3782777A4 (en) ARM TYPE SUPPORT DEVICE
CL2018000791S1 (es) Automóvil
EP3529267C0 (en) T CELL RECEPTOR
DK3649043T3 (da) Flugtsystem
DK3621871T3 (da) Flugtsystem
CL2020000224S1 (es) Automóvil.
DK3668806T3 (da) Signaleringsmekanisme.
CL2019001123S1 (es) Cepillo de dientes.
CL2019001121S1 (es) Cepillo de dientes.
CL2019003770S1 (es) Dispositivo de seguridad.